Associated Papers
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
Hirotsu Y et al.
Scientific Reports, 2024
EGFR Mutation Detection in Brazilian Patients With Non-Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing.
Montella T et al.
Jco Global Oncology, 2023
Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study.
Chamorro DF et al.
Targeted Oncology, 2023
Analysis of single-nucleotide polymorphisms in genes associated with triple-negative breast cancer.
G V et al.
Frontiers in Genetics, 2022
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
Hong TH et al.
Journal for Immunotherapy of Cancer, 2020
EGFR mutation status in a series of Turkish non-small cell lung cancer patients.
Calibasi-Kocal G et al.
Biomedical Reports, 2020
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy.
Ghafoor Q et al.
Pathology Oncology Research : Por, 2018
Evolution of oncogenic signatures of mutation hotspots in tyrosine kinases supports the atavistic hypothesis of cancer.
Chen W et al.
Scientific Reports, 2018
Clinical Analysis of Uncommon Epidermal Growth Factor Receptor Mutations in 16 Cases of Nonsmall Cell Lung Cancer.
Hu AM et al.
Chinese Medical Journal, 2018
Epidermal growth factor receptor somatic mutation analysis in 354 Chinese patients with non-small cell lung cancer.
Quan X et al.
Oncology Letters, 2018
Epidermal growth factor receptor T790M mutation: A major culprit in the progression of epidermal growth factor receptor-driven non-small cell lung cancer and the role of repeat biopsy.
Aggarwal S et al.
Indian Journal of Cancer, 2017
Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing.
Jin Y et al.
Oncotarget, 2016
Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance.
Improta G et al.
Oncology Letters, 2016
Structural Stability and Flexibility Direct the Selection of Activating Mutations in Epidermal Growth Factor Receptor Kinase.
Paladino A et al.
Journal of Chemical Information and Modeling, 2015
A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.
Ai X et al.
Amino Acids, 2014
EGFR mutation status in brain metastases of non-small cell lung carcinoma.
Burel-Vandenbos F et al.
Journal of Neuro-oncology, 2013
Drug resistance missense mutations in cancer are subject to evolutionary constraints.
Friedman R
Plos One, 2013
Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy.
Nie W et al.
International Journal of Oncology, 2012
The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
Gately K et al.
Journal of Clinical Pathology, 2012
[Experience on epidermal growth factor receptor gene mutation analysis in non-small cell lung cancer].
Zhang J et al.
Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology, 2011
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Wu JY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.
Shukuya T et al.
Cancer Science, 2011
The energy landscape analysis of cancer mutations in protein kinases.
Dixit A et al.
Plos One, 2011
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.
Bronte G et al.
Cancer Treatment Reviews, 2010
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
Pirker R et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2010
Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation.
Masago K et al.
Case Reports in Oncology, 2010
Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
Kancha RK et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2009
Epidermal growth factor receptor mutations in lung cancer.
Sharma SV et al.
Nature Reviews. Cancer, 2007
[Mutations in the epidermal growth factor receptor: structure and biological function in human tumors].
Pedersen MW et al.
Ugeskrift for Laeger, 2006
Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations.
Sakurada A et al.
Clinical Lung Cancer, 2006
Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
Chou TY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2005
Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review.
Patel GK et al.
Journal of Cancer Research and Therapeutics, 0